ClinicalTrials.gg
TerminatedNCT04253236ASCEND-WAIHAUpdated Jul 28, 2022Results posted

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

A Phase 2 interventional study of RVT-1401 680 mg/weekly and RVT-1401 340 mg/weekly in Warm Autoimmune Hemolytic Anemia, sponsored by Immunovant Sciences GmbH. Terminated at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-28.

Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.

Read the detailed description

This is a Phase 2, non-randomized, sequential, open-label study to investigate the safety, tolerability, PK, PD, and efficacy of RVT-1401 (680 mg/weekly and 340 mg/weekly) in patients with Warm Autoimmune Hemolytic Anemia that is worsening or refractory in spite of therapy with steroids and or immunosuppressants or worsening with steroid or immunosuppressant taper. Two cohorts of participants will be enrolled in a non-randomized sequential approach. Participants will be enrolled into Cohort 1 (680 mg/weekly) first followed by Cohort 2 (340 mg/weekly).

Following the initial dose at the Baseline Visit (Week 1, Day 1), study visits will occur weekly throughout the treatment period. Following the final dose at Week 12, visits will occur weekly through Week 14 and then at Week 16 and Week 20. Safety, PK, PD, and clinical assessments will be collected throughout the study.

Each participant will participate in the study for up to approximately 24 weeks: up to a 4-week screening period, a 12-week treatment period, and an 8-week follow up period.

02

Conditions studied

  • Warm Autoimmune Hemolytic Anemia
03

In context

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

This study's enrollment of 5 is below the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.

Browse Anemia, Hemolytic, Autoimmune studies →

Lead sponsor

Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age.
  2. Diagnosis of primary or secondary WAIHA as documented by a positive direct antiglobulin test (DAT) specific for anti-IgG alone or anti-IgG plus C3d.
  3. Secondary WAIHA may only include Stage 0 chronic lymphocytic leukemia (CLL) in which separate treatment is not indicated, nor anticipated to require active management for the duration of the study.
  4. Have failed or not tolerated at least one prior WAIHA treatment regimen as per local standards (e.g., , rituximab, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil (MMF), danazol, or vincristine). Failure is defined as worsening or disease despite steroids and or .
  5. Participants with splenectomy ≥3 months from Day 1 who are up to date on vaccinations (based on age and local guidance) are allowed.
  6. At Screening and Baseline, subject's level must be \<10 g/dL and the subject must have documented symptoms related to anemia (e.g., weakness, dizziness, fatigue, shortness of breath, chest pain).
  7. Subject's concurrent treatment for WAIHA may consist only of steroids (stable dose for at least two weeks prior to Day 1), immunosuppressant therapy (azathioprine, MMF, or cyclosporine) that has been at a stable dose for at least four weeks prior to Day 1, or erythropoietin (stable dose for at least 6 weeks prior to Day 1). [Note: starting doses of WAIHA therapy must be maintained throughout the study except in the case of a rescue medication as per local standards for safety. Steroid taper down to 10 mg/day will be allowed for participants who achieve response for at least 2 weeks.]
  8. A female participant is eligible to participate if she is of:

    1. Non- defined as pre-menopausal females with a documented bilateral tubal ligation, bilateral oophorectomy (removal of the ovaries) or hysterectomy; hysteroscopic sterilization, or defined as 12 months of spontaneous amenorrhea.
    2. Child-bearing potential and agrees to use one of the methods listed in the protocol for an appropriate period of time (as determined by the product label or Principal Investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female participants must agree to use contraception until 90 days after the last dose of study treatment.
  9. Male participants must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study treatment until 90 days after the last dose of study treatment.
  10. Willing and capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form.

Other, more specific inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with other types of AIHA (e.g., cold antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or paroxysmal cold hemoglobinuria).
  2. Participants requiring more than 2 units of RBC per week in the 2 weeks prior to Screening and Baseline.
  3. Use of rituximab, any monoclonal antibody for immunomodulation, or proteasome inhibitor, within the past 3 months prior to Screening.
  4. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 60 days before Screening.
  5. Total IgG level \<6 g/L (at Screening).
  6. \<1000 cells/mm3(at Screening).

Other, more specific exclusion criteria are defined in the protocol.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections

    Drug: RVT-1401 680 mg/weekly

  • Experimental
    Cohort 2

    Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections

    Drug: RVT-1401 340 mg/weekly

Interventions

  • DrugRVT-1401 680 mg/weekly

    Drug page: HBM9161

    Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401

  • DrugRVT-1401 340 mg/weekly

    Drug page: HBM9161

    Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401

06

What researchers measure

Primary outcomes

  1. Number of Responders at Week 13

    Responders were defined as the participants with level of hemoglobin (Hb) \>=10 grams per deciliter (g/dL) with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous two weeks.

    Time frame: Week 13

  2. Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death

    AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Clinically significant changes determined by the Investigator such as vital signs, Electrocardiograms (ECGs), and clinical laboratory values were also reported as AEs. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

    Time frame: Up to Week 20

Secondary outcomes

  1. Time to Response

    The time to response was defined as the amount of time to achieve response (Hb levels \>=10 g/dL with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous 2 weeks).

    Time frame: Up to Week 13

  2. Time to Achieving Hb Levels in the Normal Range

    Time to achieving Hb levels in the normal range was assessed.

    Time frame: Up to Week 13

  3. Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score

    The FACIT-F scale was a validated scale which measured the physical, emotional and social implications of fatigue, one of the key clinical manifestations of warm autoimmune hemolytic anemia. Scores ranged from 0-52, a higher score indicated a higher quality of life. A score of less than 30 indicated severe fatigue. The scale took approximately 5-10 minutes to complete.

    Time frame: Up to Week 13

  4. Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale

    The MRC Breathlessness scale is a questionnaire that consisted of 5 statements about perceived Breathlessness and the focus of the scale was to quantify the disability associated with breathlessness. Score ranged from Grade 0 (limited to no disability) to Grade 4 (severe disability); higher score indicated severe disability.

    Time frame: Up to Week 13

  5. Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score

    The EQ-5D-3L is a validated measurement of health-related quality of life. The scale consists of 2 components, the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems; a lower score indicated better quality of life. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0).

    Time frame: Up to Week 20

  6. Concentration of RVT-1401 Pre-dose

    Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic (PK) RVT-1401.

    Time frame: Pre-dose, Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12 and 13 post-dose

  7. Number of Participants With Presence of Anti-RVT 1401 Antibodies

    Blood samples were collected at indicated time points to determine presence of anti-RVT 1401 antibodies. Participants with presence of anti-RVT 1401 antibodies is reported

    Time frame: Pre-dose on Weeks 1, 3, 5, 8, 13 and Week 20

  8. Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4)

    Blood samples were collected at indicated time points for pharmacodynamic (PD) analysis of serum total IgG and IgG subclasses (1-4) concentrations. Participants with changes in levels of Total IgG and IgG Subclasses (1-4) is reported.

    Time frame: Up to Week 20

07

Results

Posted Jul 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Started50
Completed20
Not completed30
Withdrew: Adverse event10
Withdrew: Safety concerns10
Withdrew: Study terminated by sponsor10

Outcome measures

PrimaryNumber of Responders at Week 13

Responders were defined as the participants with level of hemoglobin (Hb) \>=10 grams per deciliter (g/dL) with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous two weeks.

Time frame:
Week 13
Reported as:
Count of participants · Participants
Number of Responders at Week 13
ParticipantsCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Number of Responders at Week 131—
PrimaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death

AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Clinically significant changes determined by the Investigator such as vital signs, Electrocardiograms (ECGs), and clinical laboratory values were also reported as AEs. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death
ParticipantsCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
TEAEs5—
SAEs1—
Treatment-related AEs4—
Deaths0—
SecondaryTime to Response

The time to response was defined as the amount of time to achieve response (Hb levels \>=10 g/dL with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous 2 weeks).

Time frame:
Up to Week 13
Reported as:
Number · Weeks
Time to Response
WeeksCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Time to Response3—
SecondaryTime to Achieving Hb Levels in the Normal Range

Time to achieving Hb levels in the normal range was assessed.

Time frame:
Up to Week 13
Reported as:
Number · Weeks
Time to Achieving Hb Levels in the Normal Range
WeeksCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Time to Achieving Hb Levels in the Normal Range5—
SecondaryNumber of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score

The FACIT-F scale was a validated scale which measured the physical, emotional and social implications of fatigue, one of the key clinical manifestations of warm autoimmune hemolytic anemia. Scores ranged from 0-52, a higher score indicated a higher quality of life. A score of less than 30 indicated severe fatigue. The scale took approximately 5-10 minutes to complete.

Time frame:
Up to Week 13
Reported as:
Count of participants · Participants
Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score
ParticipantsCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score3—
SecondaryNumber of Participants With Change in Medical Research Council (MRC) Breathlessness Scale

The MRC Breathlessness scale is a questionnaire that consisted of 5 statements about perceived Breathlessness and the focus of the scale was to quantify the disability associated with breathlessness. Score ranged from Grade 0 (limited to no disability) to Grade 4 (severe disability); higher score indicated severe disability.

Time frame:
Up to Week 13
Reported as:
Count of participants · Participants
Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale
ParticipantsCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale4—
SecondaryNumber of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score

The EQ-5D-3L is a validated measurement of health-related quality of life. The scale consists of 2 components, the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems; a lower score indicated better quality of life. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0).

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score
ParticipantsCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score4—
SecondaryConcentration of RVT-1401 Pre-dose

Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic (PK) RVT-1401.

Time frame:
Pre-dose, Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12 and 13 post-dose
Reported as:
Geometric mean · Milligrams per liter
Concentration of RVT-1401 Pre-dose
Milligrams per literCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Concentration of RVT-1401 Pre-doseNA ± NA—
SecondaryNumber of Participants With Presence of Anti-RVT 1401 Antibodies

Blood samples were collected at indicated time points to determine presence of anti-RVT 1401 antibodies. Participants with presence of anti-RVT 1401 antibodies is reported

Time frame:
Pre-dose on Weeks 1, 3, 5, 8, 13 and Week 20
Reported as:
Count of participants · Participants
Number of Participants With Presence of Anti-RVT 1401 Antibodies
ParticipantsCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Number of Participants With Presence of Anti-RVT 1401 Antibodies0—
SecondaryNumber of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4)

Blood samples were collected at indicated time points for pharmacodynamic (PD) analysis of serum total IgG and IgG subclasses (1-4) concentrations. Participants with changes in levels of Total IgG and IgG Subclasses (1-4) is reported.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4)
ParticipantsCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Total IgG5—
IgG Subclasses (1-4)5—

Adverse events

Collected over All-cause mortality, non-serious TEAEs and SAEs were collected up to Week 20 in Cohort 1.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: RVT-1401 680 mg/Week0/5 (0%)1/5 (20%)5/5 (100%)
Cohort 2: RVT-1401 340 mg/Week———
Most frequent serious events
Most frequent serious events
EventCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
Immune thrombocytopeniaBlood and lymphatic system disorders1/5—
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/Week
HypoalbuminaemiaMetabolism and nutrition disorders3/5—
Oedema peripheralGeneral disorders2/5—
FatigueGeneral disorders2/5—
RhinitisInfections and infestations1/5—
ParaesthesiaNervous system disorders1/5—
Non-cardiac chest painGeneral disorders1/5—
CataractEye disorders1/5—
Muscle spasmsMusculoskeletal and connective tissue disorders1/5—
NauseaGastrointestinal disorders1/5—
HypocalcaemiaMetabolism and nutrition disorders1/5—

Baseline characteristics

Safety Population: all participants who received at least one dose of study treatment. Only data for Cohort 1 is presented as study was terminated early prior to completion of dosing all participants in Cohort 1 and and Cohort 2 was not initiated.

Age, Categorical
Age, Categorical(Participants)Cohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/WeekTotal
<=18 years000
Between 18 and 65 years404
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/WeekTotal
Female303
Male202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/WeekTotal
Hispanic or Latino000
Not Hispanic or Latino505
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: RVT-1401 680 mg/WeekCohort 2: RVT-1401 340 mg/WeekTotal
American Indian or Alaska Native000
Asian404
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101
More than one race000
Unknown or Not Reported000
08

Study locations

21 sites
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Massachusetts General Hospital Cancer Center - Hematology/Oncology
    Boston, Massachusetts 02114, United States
  • University of Michigan - Internal Medicine Division of Hematology/Oncology
    Ann Arbor, Michigan 48109, United States
  • Leo W. Jenkins Cancer Center
    Greenville, North Carolina 27834, United States
  • Ha'Emek Medical Center
    Afula, 1834111, Israel
  • Carmal MC
    Haifa, 3436212, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam, 13620, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Seoul National University Hospital - Department of Internal Medicine
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05-505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Hospital Universitario Quirónsalud Madrid
    Barcelona, 08035, Spain
  • Hospital Universitario Quirón
    Madrid, 28223, Spain
  • Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Faculty of Medicine, Chiang Mai University, Maharaj Nakorn Chiang Mai Hospital
    Chiang Mai, 50200, Thailand
  • Faculty of Medicine, Prince of Songkla University,Songklanagarind Hospital
    Hat Yai, 90110, Thailand
  • Faculty of Medicine, Khon Kaen University, Srinagarind Hospital
    Khon Kaen, 40002, Thailand
  • Royal Cornwall Hospital
    Truro, TR1 3LJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Apr 2021, 7 months.

Results were first posted in Jul 2022, 1 year 3 months after primary completion. A results delay was requested in Mar 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2020
First posted
Feb 5, 2020
StartActual
Aug 11, 2020
Primary completionActual
Apr 1, 2021
CompletionActual
Apr 1, 2021
Results delay requested
Mar 16, 2022
Results first posted
Jul 28, 2022
Last update
Jul 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04253236
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Aug 11, 2020
Primary completion
Apr 1, 2021
Completion
Apr 1, 2021
Results posted
Jul 28, 2022
Last update
Jul 28, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion